chen, chenyan – page 5 – eisai china lnc.-爱游戏app官网入口

for its contributions towards patients with liver disease through the eisai-originated orally available kinase inhibitor lenvima®

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it received the president’s award at the 8th technology management and innovation awards held by the japan techno-economics society (jates)*. the award was presented to eisai for its discovery of the orally available kinase inhibitor lenvima®(generic name: lenvatinib mesylate) and its contributions towards patients with liver disease.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has launched the in-house discovered and developed antiepileptic drug (aed) fycompa®, (product name in china: 卫克泰®, generic name perampanel) for use in adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.

sysmex corporation (hq: kobe, japan; chairman and ceo: hisashi ietsugu; “sysmex”) and eisai co., ltd. (hq: tokyo, japan; ceo: haruto naito; “eisai”) announced that the most recent data from the project to develop a method of diagnosing alzheimer’s disease (ad) using blood plasma was presented at the 13th clinical trials on alzheimer’s disease (ctad) conference, held virtually from november 4 to 7, 2020.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: halaven®, “eribulin”) will be presented during the 42nd san antonio breast cancer symposium (sabcs2019). the symposium will be held from december 10 through 14, 2019, in san antonio, texas in the united states.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) has announced that lenvima (generic name: lenvatinib), the orally available kinase inhibitor discovered by eisai, has been accepted by the national medical products administration of china for an application for the additional indication of differentiated thyroid cancer. this application for additional indication marks the second in china following the indication for hepatocellular carcinoma, which was approved in september 2018.